Monopar Therapeutics Inc (MNPR) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Monopar Therapeutics Inc. has announced the green light from the Human Research Ethics Committee in Australia to begin a Phase 1 trial for its pioneering radiopharmaceutical, MNPR-101-Zr. This marks a significant milestone for the company as it moves forward with the development of this innovative treatment option.
For further insights into MNPR stock, check out TipRanks’ Stock Analysis page.